Palisade Bio (PALI) Accounts Payables (2010 - 2026)
Palisade Bio (PALI) reported Accounts Payables of $2.7 million for Q1 2026, up 261.88% year-over-year from $745000.0 in Q1 2025, and up 251.5% on a QoQ basis from $767000.0 in Q4 2025.
Palisade Bio (PALI) has 17 years of Accounts Payables data on file, last reported at $2.7 million in Q1 2026.
- Quarterly Accounts Payables rose 261.88% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 261.88% YoY) and the FY2025 annual result came in at $767000.0, down 30.59% from the prior year.
- Accounts Payables grew to $2.7 million in Q1 2026 per PALI's latest filing, from $767000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $2.7 million in Q1 2026 and bottomed at $366000.0 in Q3 2024.
- The 5-year median for Accounts Payables is $950000.0 (2023), against an average of $1.1 million.
- The widest annual swing landed in 2024, when Accounts Payables slumped 61.47%; it then jumped 289.62% in 2025.
- Tracing PALI's Accounts Payables over 5 years: stood at $1.8 million in 2022, then slumped by 60.32% to $698000.0 in 2023, then jumped by 58.31% to $1.1 million in 2024, then plunged by 30.59% to $767000.0 in 2025, then soared by 251.5% to $2.7 million in 2026.
- Per Business Quant, the three latest PALI Accounts Payables figures stand at $2.7 million (Q1 2026), $767000.0 (Q4 2025), and $1.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | 2.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.70 Mn |
| Dec 31, 2025 | 767,000.00 |
| Sep 30, 2025 | 1.43 Mn |
| Jun 30, 2025 | 1.37 Mn |
| Mar 31, 2025 | 745,000.00 |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 366,000.00 |
| Jun 30, 2024 | 514,000.00 |
| Mar 31, 2024 | 459,000.00 |
| Dec 31, 2023 | 698,000.00 |
| Sep 30, 2023 | 950,000.00 |
| Jun 30, 2023 | 922,000.00 |
| Mar 31, 2023 | 706,000.00 |
| Dec 31, 2022 | 1.76 Mn |
| Sep 30, 2022 | 1.73 Mn |
| Jun 30, 2022 | 1.04 Mn |
| Mar 31, 2022 | 1.15 Mn |
| Dec 31, 2021 | 1.32 Mn |
| Sep 30, 2021 | 1.38 Mn |
| Jun 30, 2021 | 1.41 Mn |
| Mar 31, 2021 | 520,913.00 |
| Dec 31, 2020 | 2.54 Mn |
| Sep 30, 2020 | 577,558.00 |
| Jun 30, 2020 | 542,976.00 |
| Mar 31, 2020 | 961,026.00 |
| Dec 31, 2019 | 824,406.00 |
| Sep 30, 2019 | 1.18 Mn |
| Jun 30, 2019 | 1.05 Mn |
| Mar 31, 2019 | 1.08 Mn |
| Dec 31, 2018 | 832,564.00 |
| Sep 30, 2018 | 835,749.00 |
| Jun 30, 2018 | 713,068.00 |
| Mar 31, 2018 | 1.17 Mn |
| Dec 31, 2017 | 875,065.00 |
| Sep 30, 2017 | 1.48 Mn |
| Jun 30, 2017 | 2.24 Mn |
| Mar 31, 2017 | 2.17 Mn |
| Dec 31, 2016 | 2.34 Mn |
| Sep 30, 2016 | 2.48 Mn |
| Jun 30, 2016 | 2.50 Mn |
| Mar 31, 2016 | 2.63 Mn |
| Dec 31, 2015 | 1.46 Mn |
| Sep 30, 2015 | 2.04 Mn |
| Jun 30, 2015 | 2.10 Mn |
| Mar 31, 2015 | 2.13 Mn |
| Dec 31, 2014 | 2.50 Mn |
| Sep 30, 2014 | 2.44 Mn |
| Jun 30, 2014 | 2.03 Mn |
| Mar 31, 2014 | 1.77 Mn |
| Dec 31, 2013 | 1.20 Mn |
| Sep 30, 2013 | 1.21 Mn |
| Jun 30, 2013 | 812,841.00 |
| Mar 31, 2013 | 1.24 Mn |
| Dec 31, 2012 | 1.20 Mn |
| Sep 30, 2012 | 1.50 Mn |
| Jun 30, 2012 | 1.15 Mn |
| Mar 31, 2012 | 1.65 Mn |
| Dec 31, 2011 | 1.84 Mn |
| Sep 30, 2011 | 1.39 Mn |
| Jun 30, 2011 | 773,008.00 |
| Dec 31, 2010 | 1.03 Mn |